Ginger Graham, the CEO of Amylin Pharmaceuticals , joined the expectation of taking the company's touch drug, Symlin, to market and the firm. However, unforeseen regulatory challenges have placed the acceptance procedure in peril.
Graham must determine how to manage the company's limited resources while also finalizing another deal that's tremendous future potential. Graham understands that Amylin's instant success is dependent upon its being able to commercialize its products but its long-term success depends on replenishing its pipeline. Can the company do it?
PUBLICATION DATE: December 09, 2008 PRODUCT #: 809011-HCB-ENG
This is just an excerpt. This case is about INNOVATION & ENTREPRENEURSHIP
Related Case Solutions & Analyses:
Cold Opportunity (A): The Nils Bergqvist Story
Don Jenkins: Resigning from the Firm
Evaluating M&Deals–Announcement Effects Risk Arbitrage and Event Risk
Japanese Banking: Crisis and Reform
Emerge Magazine: The Business of Ethnic Publishing
Shanghai Zhangjiang Hi-Tech Park Development Co., Ltd.
Google Inc.
CASE ANALYSIS: TATA COMMUNICATIONS EMERGING MARKET GROWTH OPPORTUNITY
North American Financial Corporation (NAF) The MLM Project (A)
Daqi Case Report
